RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > The EU Paediatric Regulation

The EU Paediatric Regulation

Posted 01 March 2008

The Paediatric Regulation1 was adopted in December 2006 by the European Parliament and the Council of Europe with the goals of improving the availability of paediatric medicines; increasing high-quality, ethical paediatric research; and increasing information about the use of medicines in the paediatric population without delaying marketing authorisation in adults or conducting unnecessary trials in children. The regulation is the end result of proposals made to encourage companies to develop medicines for children and follows extensive consultation with stakeholders on the first legislative texts.2,3 This article summarizes the initiatives taken by the European Medicines Agency (EMEA) to implement this regulation, which came into force on 26 January 2007.


© 2022 Regulatory Affairs Professionals Society.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.